Wednesday 18 November 2020
Co-chaired by Dr Maria Carrillo and Professor Philip Scheltens, this workshop covered two themes selected based on their importance in the field: early detection and biomarkers; and advances in treatment. Speakers included Professor Oskar Hansson, Dr Cath Mummery, Dr Eric Siemers and Professor Reisa Sperling.
Friday 5 February 2021
Co-chaired by Professor Brian Lawlor and Paul Hogan, this workshop covered progress made in the field of care and the challenges that remain, exploring models of care, the burden of caregivers, and art and music in dementia. Professor Felicity Barker, Professor Louise Robinson, Professor Mary Sano and Dr Samir Sinha presented their thinking ahead of an open discussion.
The prevention workshop tracked progress made on reducing the risk of dementia, and was led by Professor Kaarin Anstey, professor of psychology and director of the University of New South Wales Ageing Futures Institute, and Professor Philippe Amouyel, general director of Fondation Plan Alzheimer (France), professor of epidemiology and public health at the University Hospital of Lille, and a member of the World Dementia Council.
Tuesday 9 February 2021
07:00 GMT London | 08:00 CET Central Europe | 12:30 IST New Delhi | 16:00 JST Tokyo | 18:00 AEDT Sydney
Professor Kaarin Anstey
Kaarin Anstey is a professor of psychology and conducts public health research into dementia risk reduction ranging from analysis of cohort studies, development of risk assessment tools, and conducting risk reduction trials. Kaarin is the director of the University of New South Wales Ageing Futures Institute and is a conjoint senior principal research scientist at Neuroscience Research Australia. She chairs the International Research Network on Dementia Prevention and is a member of the governance committee of the Global Council on Brain Health, an initiative supported by AARP.
Professor Philippe Amouyel
Philippe Amouyel is general director of Fondation Alzheimer (France), professor of epidemiology and public health at the University Hospital of Lille, and a member of the World Dementia Council. Since 1998, he has headed a research unit of 110 people dedicated to public health and the molecular epidemiology of age-related diseases. He has published more than 850 scientific articles and participated in the discovery of 90% of the confirmed genetic loci predisposing to sporadic Alzheimer’s disease. At the European level, Philippe also chairs the European Joint Programming Initiative on Research on Neurodegenerative Diseases (JPND) and Alzheimer’s in particular. The main objective of JPND is to combine the strength of European and global research to tackle these diseases more efficiently.
Professor Carol Brayne
Carol Brayne CBE is a Professor of Public Health Medicine and Co-Chair of the Cambridge Public Health Interdisciplinary Centre at the University of Cambridge. She is a medically qualified epidemiologist and public health academic. Her main research has been longitudinal studies of older people following changes over time with a public health perspective and focus on the brain. She is lead principal investigator in the MRC CFA Studies and other population based studies and has played a lead role in teaching and training in epidemiology and public health at Cambridge University. She is a Fellow of the Academy of Medical Sciences and an NIHR Senior Investigator Emeritus.
Dr Michele Cecchini
Michele Cecchini is responsible for the programme on Public Health at the OECD – the Organisation for Economic Co-operation and Development. Michele’s research interests include priority setting and programme evaluation of policies influencing population health. He is the editor, author and co-author of a large number of publications on the economic aspects of public health, including the recent OECD flagship publications on antimicrobial resistance, overweight and alcohol. Michele represents OECD in the board of the Global AMR R&D Hub and holds a position of adjunct professor in applied health economics at the School of Public Health of the University of Siena (Italy). Previously, he held a visiting position at the Duke-NUS Graduate Medical School in Singapore and served as a temporary advisor to a number of government and international agencies, including WHO, IARC, EC and the World Bank. After obtaining a degree in Medicine and Surgery from the University of Genoa, Michele completed his specialist training in Public Health at the University of Siena. He also obtained a master’s degree in Health Policy, Planning and Financing from the London School of Economics and the London School of Hygiene and Tropical Medicine and a PhD from Imperial College London.
Dr Yoshiki Niimi
Eric Siemers has over 25 years of experience in clinical trials of neurodegenerative disease. His research focus is on the use of biomarkers in investigational drug research, the development of trial designs that fully characterize the effects of investigational drugs on chronic diseases, and more specifically, the development of strategies for treating individuals before the onset of symptoms of neurodegenerative diseases. Dr Siemers most recently served as a distinguished medical fellow for Eli Lilly and Company’s Alzheimer’s Disease Global Development Team, where he was responsible for the design and implementation of five large Phase III clinical studies, in addition to playing a major collaborative role in 2 public-private partnership studies. Dr Siemers earned his medical degree from the Indiana University School of Medicine (US).
Other events in the series
To inform the dementia landscape report, the Council is hosting virtual workshops for international dementia leaders focusing on key themes of research, care and prevention that were identified at the London dementia summit in 2013. In addition, the Council is hosting smaller roundtables that will focus on additional key themes and new policy priorities that we have agreed to highlight in the report, including data sharing and dementia registries, technology in the health and social care sector, and the impact of dementia on low- and middle-income countries. See more below.